Sanofi made early Q3 global availability of BEYFORTUS® (nirsevimab) to stock up on the healthcare providers ahead of the 2025–2026 respiratory syncytial virus (RSV) season, which generally runs from November through March.
Advancements in Immune Thrombocytopenia (ITP)
Sanofi shared Phase 3 LUNA 3 study results on rilzabrutinib’s capability to treat the underlying immune dysregulation in ITP. An oral presentation reported rates of platelet response according to International Working Group (IWG) criteria—a major clinical endpoint for making treatment decisions. Two poster presentations reported the first efficacy and safety results from the LUNA 3 open-label period and investigated platelet count fluctuation in patients on rilzabrutinib.
Rilzabrutinib is also under review in the U.S., EU, and China to treat ITP, awaiting the U.S. Food and Drug Administration’s decision by August 29, 2025. The FDA has also granted the treatment fast-track designation for its ability to meet unmet medical needs.
Our third year of providing RSV protection marks a transformative era in infant health. Backed by more than 40 real-world studies involving 250,000 immunized infants, BEYFORTUS has consistently proven itself as an effective RSV immunization. To meet growing demand since launch, we have meticulously primed our global distribution network to ensure BEYFORTUS will continue to deliver significant public health impact and offer high, sustained efficacy for infants regardless of underlying health conditions or the timing of when they are born.
Thomas Triomphe
Enhancing Hemophilia Treatment Options
Sanofi also presented data supporting its hemophilia leadership. The presentations highlighted the value of ALTUVIIIO and the recently launched Qfitlia, both created to provide additional treatment options and better patient outcomes. These treatments seek to meet the ongoing unmet needs of patients and their caregivers by delivering innovative solutions for hemophilia treatment.
Last Modified:
